Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > For Notable. From "Science" 9Dec 21

<< Previous

Bullboard Posts

Next >>

Comment by askretkaon Feb 16, 2022 7:17pm

154 Views

Post# 34435937

RE:RE:RE:For Notable. From "Science" 9Dec 21

Thanks for the Feb 14 link. https://www.technologynetworks.com/cancer-research/articles/harnessing-the-immune-system-to-treat-cancer-358080

-----------------

"But the downside to this approach is that “for about 80% of cancers, you can't find them, you don't know where they are, they're not amenable to a needle. Therefore, intratumoral delivery doesn't work for most human cancers.”

-----------------------------

This is advantage Pela with our ability to deliver Pela by IV.
------------------------------------------------------

Cheers@!

<< Previous

Bullboard Posts

Next >>

Boeing workers end strike, return to work